Yessica Zamudio-Cuevas1, Gabriela Angélica Martínez-Nava1, Karina Martínez-Flores1, Lucio Ventura-Ríos2, Janitzia Vazquez-Mellado3, Pedro Rodríguez-Henríquez4, Carlos Pineda5, Rafael Franco-Cendejas6, Carlos Alberto Lozada-Pérez7, Javier Fernández-Torres8,9. 1. Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra-Ibarra (INR-LGII), Calzada México-Xochimilco 289, Colonia Arenal de Guadalupe, 14389, Mexico City, Tlalpan, Mexico. 2. Laboratorio de Ultrasonido Músculo-Esquelético Articular, INR-LGII, Mexico City, Mexico. 3. Department of Rheumatology, Hospital General de México Eduardo Liceaga, Dr. Balmis 148. Doctores, 06720, México City, Cuauhtémoc, Mexico. 4. Department of Rheumatology, Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, Belisario Domínguez Seccion 16, 14080, Mexico City, Tlalpan, Mexico. 5. División de Enfermedades Músculo-Esqueléticas y Reumáticas, INR-LGII, Mexico City, Mexico. 6. División de Infectología, INR-LGII, Mexico City, Mexico. 7. Servicio de Reumatología, INR-LGII, Mexico City, Mexico. 8. Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra-Ibarra (INR-LGII), Calzada México-Xochimilco 289, Colonia Arenal de Guadalupe, 14389, Mexico City, Tlalpan, Mexico. javier_astrofan@hotmail.com. 9. Biology Department, Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, 04510, Mexico City, Coyoacán, Mexico. javier_astrofan@hotmail.com.
Abstract
INTRODUCTION/ OBJECTIVES: Few studies have addressed the detection and clinical impact of different crystals in patients with diverse rheumatologic diagnoses in Latin America. The aim of this study was to assess the consistency between the clinical referring diagnosis and the identification of crystals, such as monosodium urate (MSU) and calcium pyrophosphate (CPP), in the synovial fluid (SF) of patients from a Mexican tertiary care institution. METHODS: We reviewed the results of 264 SF analyses to identify any changes in diagnosis upon SF analysis. We reported patient medical file data on sex, age, diagnosis, and microscopic SF analysis results. We performed consistency analyses between referring diagnoses and SF findings with McNemar's test. RESULTS: The prevalence of MSU crystals in SF was noted in 89.1% of gout cases and 9.09% of cases of calcium pyrophosphate disease (CPPD). CPP crystals were present in 54.5% of CPPD cases, 42.9% of osteoarthritis (OA) cases, and 7.27% of gout cases. Calcium hydroxyapatite (HA) crystals were identified in 5.45% of gout cases, 33.3% of rheumatoid arthritis (RA) cases, 57.1% of OA cases, and 63.6% of CPPD cases. Cholesterol and lipid crystals were present in small proportions in RA cases. Glucocorticoid crystals were observed in 1.85% of gout cases, 44.4% of RA cases, and 42.9% of OA cases. We observed an association of MSU identification with clinical suspicion of gout (P = 0.08), CPP with OA (P = 0.26) and CPPD (P = 0.50). An association was noted between HA and the diagnosis of CPPD (P = 0.84) and OA (P > 0.99). The number of initial diagnoses that changed upon SF analysis was 14.3%. CONCLUSIONS: SF analysis has major diagnostic value regarding MSU crystals and gout. Our findings underscore the importance of SF crystal analysis in identifying the prevalence of crystals in the Mexican population. SF analysis provides for better diagnosis of crystal arthropathies and improves the quality of the medical care that the patient receives. Key Points • Synovial fluid analysis in laboratories from developing countries has been scarce. • In some cases, the initial diagnosis is modified after of synovial fluid analysis. • This study confirmed that synovial fluid analysis exhibits major diagnostic value for urate crystals and gout.
INTRODUCTION/ OBJECTIVES: Few studies have addressed the detection and clinical impact of different crystals in patients with diverse rheumatologic diagnoses in Latin America. The aim of this study was to assess the consistency between the clinical referring diagnosis and the identification of crystals, such as monosodium urate (MSU) and calcium pyrophosphate (CPP), in the synovial fluid (SF) of patients from a Mexican tertiary care institution. METHODS: We reviewed the results of 264 SF analyses to identify any changes in diagnosis upon SF analysis. We reported patient medical file data on sex, age, diagnosis, and microscopic SF analysis results. We performed consistency analyses between referring diagnoses and SF findings with McNemar's test. RESULTS: The prevalence of MSU crystals in SF was noted in 89.1% of gout cases and 9.09% of cases of calcium pyrophosphate disease (CPPD). CPP crystals were present in 54.5% of CPPD cases, 42.9% of osteoarthritis (OA) cases, and 7.27% of gout cases. Calcium hydroxyapatite (HA) crystals were identified in 5.45% of gout cases, 33.3% of rheumatoid arthritis (RA) cases, 57.1% of OA cases, and 63.6% of CPPD cases. Cholesterol and lipid crystals were present in small proportions in RA cases. Glucocorticoid crystals were observed in 1.85% of gout cases, 44.4% of RA cases, and 42.9% of OA cases. We observed an association of MSU identification with clinical suspicion of gout (P = 0.08), CPP with OA (P = 0.26) and CPPD (P = 0.50). An association was noted between HA and the diagnosis of CPPD (P = 0.84) and OA (P > 0.99). The number of initial diagnoses that changed upon SF analysis was 14.3%. CONCLUSIONS: SF analysis has major diagnostic value regarding MSU crystals and gout. Our findings underscore the importance of SF crystal analysis in identifying the prevalence of crystals in the Mexican population. SF analysis provides for better diagnosis of crystal arthropathies and improves the quality of the medical care that the patient receives. Key Points • Synovial fluid analysis in laboratories from developing countries has been scarce. • In some cases, the initial diagnosis is modified after of synovial fluid analysis. • This study confirmed that synovial fluid analysis exhibits major diagnostic value for urate crystals and gout.
Authors: Hein J E M Janssens; Mathijs Janssen; Eloy H van de Lisdonk; Jaap Fransen; Piet L C M van Riel; Chris van Weel Journal: Ann Rheum Dis Date: 2009-11-11 Impact factor: 19.103
Authors: William J Taylor; Jaap Fransen; Nicola Dalbeth; Tuhina Neogi; H Ralph Schumacher; Melanie Brown; Worawit Louthrenoo; Janitzia Vazquez-Mellado; Maxim Eliseev; Geraldine McCarthy; Lisa K Stamp; Fernando Perez-Ruiz; Francisca Sivera; Hang-Korng Ea; Martijn Gerritsen; Carlo A Scire; Lorenzo Cavagna; Chingtsai Lin; Yin-Yi Chou; Anne-Kathrin Tausche; Geraldo da Rocha Castelar-Pinheiro; Matthijs Janssen; Jiunn-Horng Chen; Ole Slot; Marco Cimmino; Till Uhlig; Tim L Jansen Journal: J Rheumatol Date: 2015-12-01 Impact factor: 4.666
Authors: Ingris Peláez-Ballestas; Luz Helena Sanin; José Moreno-Montoya; José Alvarez-Nemegyei; Rubén Burgos-Vargas; Mario Garza-Elizondo; Jacqueline Rodríguez-Amado; Maria-Victoria Goycochea-Robles; Marco Madariaga; Jorge Zamudio; Natalia Santana; Mario H Cardiel Journal: J Rheumatol Suppl Date: 2011-01
Authors: Amir Qaseem; Robert M McLean; Melissa Starkey; Mary Ann Forciea; Thomas D Denberg; Michael J Barry; Cynthia Boyd; R Dobbin Chow; Nick Fitterman; Linda L Humphrey; Devan Kansagara; Scott Manaker; Sandeep Vijan; Timothy J Wilt Journal: Ann Intern Med Date: 2016-11-01 Impact factor: 25.391
Authors: Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor Journal: Ann Rheum Dis Date: 2015-10 Impact factor: 19.103
Authors: P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin Journal: Ann Rheum Dis Date: 2016-07-25 Impact factor: 19.103